CAS: 14930-96-2; Cytochalasin B

该化合物是一种自然产生的藻类,产自各种真菌,特别是原菌*肝素* .众所周知,它能够抑制聚合作用,干扰细胞骨骼动态,影响细胞运动,分裂和形状.该化合物的分子公式为C_22H_29N_3O_5,具有包括内酯环和多种功能组的复杂结构.Cytochalasin B经常用于生物研究,研究细胞过程,特别是在细胞生物学和药理学领域.其行动机制涉及行为丝状的结端,防止其延长.此外,已对潜在的治疗应用进行了调查,尽管其使用主要限于实验室环境,因为其细胞毒性效应.在处理Cytochalasin B时,必须采取安全防范措施,因为它可能对细胞功能产生重大影响,如果管理不当,可能会对健康造成风险.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号86527-62-0 (3E,5R,9S,11E,1... | CAS号86527-63-1 (3E,5R,9S,11E,1... | CAS号86527-45-9 (3S,3aS,4R,6aR,... | CAS号86527-61-9 (3S,3aS,10S,14R... | CAS号86542-46-3 (1E,4S,8R,9E,12... | CAS号14110-64-6 细胞松弛素A

合成工艺路线路线简述

    7,20-O,O'-Diacetyl-Cytochalasin B 反应生成细胞松弛素b
    参考文献:硫醇酯的活化.细胞松弛素a和b的部分合成.
    标题:硫醇酯的活化.细胞松弛素a和b的部分合成.
    摘要:
    Doi:10.1021/ja00462A049

    海关参考信息

    专利信息


    专利号:US-8697385-B1
    优先权日:2009-10-06
    标 题 :Protein controlling synthesis of collagen and associated methods
    发明人:STEFANOVIC BRANKO
    权利人:UNIV FLORIDA STATE RES FOUND; UNIV FLORIDA STATE RES FOUND
    摘要:A method of screening an agent for ability to interfere with collagen synthesis includes the steps of reacting a polypeptide having an amino acid sequence comprising SEQ ID NO: 1 with collagen mRNAs in the presence of the agent and detecting if the agent has interfered with binding of the polypeptide to the mRNAs. Another method includes the steps of reacting the polypeptide with nonmuscle myosin filaments in the presence of the agent and detecting if the agent has interfered with binding of the polypeptide to the nonmuscle myosin filaments.

    专利号:US-2008267981-A1
    优先权日:2004-06-30
    标题:Compositions and Methods for Delivery of Antitumor Agents
    发明人:JANDA KIM D; WIRSCHING PETER; BOGER DALE L
    权利人:SCRIPPS RESEARCH INST
    摘要:Methods for treating a neoplastic disease with an antibody-cytotoxin conjugate molecule, methods of synthesizing an antibody-cytotoxin conjugate molecule are provided. Compounds that are useful as antibody-cytotoxin conjugate molecule or useful in the synthesis of these molecules are also provided.

    专利号:US-6284787-B1
    优先权日:1993-12-21
    标题 :Use of R-(+)-α-lipoic acid, R-(−)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae
    发明人:WESSEL KLAUS; BORBE HARALD; ULRICH HEINZ; HETTCHE HELMUT; BISSWANGER HANS; PACKER LESTER; KLIP AMIRA
    权利人:ASTA MEDICA AG
    摘要:The invention relates to the use of R-(+)-alpha-lipoic acid, R-(-)-dihydrolipoic acid or their metabolites, salts, esters and amides for the synthesis of drugs for the treatment of diabetes mellitus of types I and II, compensated and decompensated insulin resistance and sequelae or late complications of diabetes mellitus, such as cataracts, polyneuropathy, nephropathy, as well as sequelae or late complications of insulin resistance. These drugs mentioned can also be used advantageously in combination with other antidiabetic drugs, particularly with insulin, and/or other additives or stabilizers or adjuvants, such as vitamin B, vitamin C, NADH, NADPH and ubiquinone.The invention furthermore relates to the use of R-(+)-alpha-lipoic acid, R-(-)-dihydrolipoic acid or their metabolites, as well as their salts, esters and amides for the preparation of drugs for the treatment of diseases with limited function of or a lowered content of the glucose transporters.

    专利号:US-10370455-B2
    优先权日:2014-12-05
    标题 :Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists
    发明人:MOLLOY MICHAEL; GUO YALIN; ROTHSTEIN JAY; ROSENZWEIG MICHAEL
    权利人:IMMUNEXT INC
    摘要:The receptor for VISTA is identified (VSIG8) as well as the use of this receptor in the identification or synthesis of agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG8 and/or VISTA and/or the VSIG8/VISTA binding interaction. These antagonists may be used to suppress VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.

    专利号:US-9650407-B2
    优先权日:2011-11-02
    标 题 :Reprogramming of cellular adhesion
    发明人:GARTNER ZEV JORDAN; SELDEN NICHOLAS SCOTT; TODHUNTER MICHAEL E; LIANG SAMANTHA ISABEL; WEBER ROBERT JOSEPH; JEE NOEL YOUNGHO; LIU JENNIFER S
    权利人:UNIV CALIFORNIA
    摘要:Disclosed are membrane-anchored polynucleotides, and compositions comprising the membrane-anchored polynucleotides. Also disclosed are the processes for the synthesis of these compounds, compositions comprising such compounds, and the use of such compounds and compositions in research and therapeutic applications.

    专利号:US-9790531-B2
    优先权日:2012-08-14
    标 题 :Enzymes and polymerases for the synthesis of RNA
    发明人:WANG YUXUN; RAMAKRISHNAN DIVAKAR; DE FOUGEROLLES ANTONIN; WHORISKEY SUSAN
    权利人:MODERNATX INC
    摘要:The invention relates to compositions and methods for the design, evolution, preparation, and/or manufacture of enzymes for use with polynucleotides, primary transcripts and mmRNA molecules.
    成都曼思特生物科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.cdmust.com
    电话: 028-87384368👤
    📞成都曼思特生物科技有限公司 ⚠️参考联系方式

    销售电话:028-87384368
    邮箱:cdmust@163.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Bianconi E, Tassinari R, Alessandrini A, Ragazzini G, Cavallini C, Abruzzo PM, Petrocelli G, Pampanella L, Casadei R, Maioli M, Canaider S, Facchin F, Ventura C. Cytochalasin B Modulates Nanomechanical Patterning and Fate in Human Adipose-Derived Stem Cells. Cells. 2022 May 12;11(10):1629. doi: 10.3390/cells11101629.
    2: Uezato T, Fujita M. Cytochalasin-B-binding proteins related to glucose transport across the basolateral membrane of the intestinal epithelial cell. J Cell Sci. 1986 Sep;85:177-85. doi: 10.1242/jcs.85.1.177. 4(12):3021-7. doi: 10.1096/fasebj.4.12.2394319. 28(11):gaac036. doi: 10.1093/molehr/gaac036.
    5: Gomzikova M, Kletukhina S, Kurbangaleeva S, Rizvanov A. Evaluation of Cytochalasin B-Induced Membrane Vesicles Fusion Specificity with Target Cells. Biomed Res Int. 2018 Apr 8;2018:7053623. doi: 10.1155/2018/7053623.

    合成参考文献


    参考文献:10.1016/s0923-2516(97)89132-7
    摘要:Crance JM, Gratier D, Guimet J, Jouan A. Inhibition of sandfly fever Sicilian virus (Phlebovirus) replication in vitro by antiviral compounds. Res Virol. 1997 Sep;148(5):353–65. doi: 10.1016/s0923-2516(97)89132-7.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知